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Adult T-cell leukemia/lymphoma is a highly inﬁltrative neoplasia of CD4þ T-lymphocytes that occurs in
about 5% of carriers infected with the deltaretrovirus human T-cell leukemia virus type 1 (HTLV-1). The
viral oncoprotein Tax perturbs cellular signaling pathways leading to upregulation of host cell factors,
amongst them the actin-bundling protein Fascin, an invasion marker of several types of cancer. However,
transcriptional regulation of Fascin by Tax is poorly understood. In this study, we identiﬁed a triple mode
of transcriptional induction of Fascin by Tax, which requires (1) NF-κB-dependent promoter activation,
(2) a Tax-responsive region in the Fascin promoter, and (3) a promoter-independent mechanism sensitive
to the Src family kinase inhibitor PP2. Thus, Tax regulates Fascin by a multitude of signals. Beyond, using
Tax-expressing and virus-transformed lymphocytes as a model system, our study is the ﬁrst to identify
the invasion marker Fascin as a novel target of PP2, an inhibitor of metastasis.
& 2015 Elsevier Inc. All rights reserved.Introduction
Adult T-cell leukemia/ lymphoma (ATL) is an incurable and
aggressive neoplasia of CD4þ T-lymphocytes that is well known for
inﬁltrations of leukemic cells into various tissues and organs like
skin, lungs, liver, gastrointestinal tract, central nervous system,
lymph nodes, and bone. ATL occurs in about 5% of carriers infected
with the tumor virus human T-cell leukemia virus type 1 (HTLV-1)
(Ishitsuka and Tamura, 2014; Matsuoka and Jeang, 2007). HTLV-1 is
a widespread delta-retrovirus that transforms CD4þ T-lymphocytes,
a process mainly initiated by the viral Tax oncoprotein (Currer et al.,
2012; Matsuoka and Jeang, 2007). Tax does not only activate viralolecular Virology, Friedrich-
garten 4, 91054 Erlangen,
22101.
angen.de (C.F. Mohr),
ainz.de (A.B. Reske-Kunz),
B. Biesinger),
).transcription through the HTLV-1 promoter located in the long
terminal repeat of the provirus, but it also induces cellular gene
expression through several signaling pathways including cyclic-
AMP response element-binding protein (CREB), serum response
factor, activator protein, and nuclear factor of kappa light chain
enhancer in B cells (NF-κB) (Grassmann et al., 2005).
The actin-bundling protein Fascin has received attention as a
tumor marker since it is important for migration and invasion of
cancer cells (Hashimoto et al., 2011; Jayo and Parsons, 2010). Fascin
is a globular protein that is expressed in endothelial, neuronal,
mesenchymal, and mature dendritic cells, but not in lymphocytes
from healthy individuals (Adams, 2004; Hashimoto et al., 2005;
Jayo and Parsons, 2010; Ross et al., 2000). Functionally, Fascin
stabilizes ﬁlamentous actin and is concentrated in podosomes,
ﬁlopodia, and invadopodia during cell migration (Adams, 2004;
Jayo and Parsons, 2010). Fascin expression is highly upregulated in
various types of cancer including breast, lung, colon, esophagus,
nasopharyngeal, pancreatic, stomach, ovary, brain, and skin cancer,
and in lymphomas/leukemias including Hodgkin's Lymphoma, and
Epstein–Barr-virus associated lymphomas (Hashimoto et al., 2011;
Fig. 1. A 1.6 kb fragment of the Fascin promoter is responsive to Tax. (a) Scheme of luciferase reporter constructs with different truncations of the human Fascin promoter
(phF). The start site of the truncation (left side) is shown as distance from the transcription start site (þ1). (b,c) Jurkat T-cells were cotransfected with different phF
constructs and pEFTax1 or the control vector pEF. After 48 h, cells were lysed. (b) Luciferase activity was measured in relative light units (RLU) and normalized on protein
content. Results are shown as mean RLU/protein7standard error (SE) of three independent experiments performed in triplicate and were compared using a t-test (*,
Po0.05). UT, untreated cells. (c) Immunoblot of Fascin, Tax-1 and ß-Actin (ActB).
C.F. Mohr et al. / Virology 485 (2015) 481–491482Hashimoto et al., 2005; Jayo and Parsons, 2010; Krikelis et al.,
2013). Fascin expression correlates with decreased overall and
disease-free survival, occurrence of metastasis, enhanced chemo-
resistance, and aggressiveness in some carcinomas (Chen et al.,
2010; Ghebeh et al., 2014; Tan et al., 2013), thus, representing a
novel therapeutic target. In cancer tissue, Fascin is accumulated on
the leading edge of cancer cells (Hashimoto et al., 2011), con-
tributes to self-seeding of cancer cells (Kim et al., 2009), and
promotes tumor progression in vivo (Schoumacher et al., 2014).Fig. 2. NF-κB signals are important for Tax-mediated activation of the 1.6 kb fragment of
carrying the 1.6 kb fragment of the human Fascin promoter (phF1.6) with putative bind
Numbers give the distance from the transcription start point (þ1). The Tax-responsive
indicated luciferase reporter constructs. After 48 h, luciferase activity was measured
respective control7SE. If not stated otherwise, three independent experiments were
Po0.01). (b) Cells were cotransfected with pcTax1, the Tax mutants M22 (NF-κB-deﬁcien
the luciferase reporter vectors HTLV-U3R (upper panel, black bars, representative resul
(lower panel, n¼3). (c) Cells were transfected with phF1.6 (20 mg) and pEFTax1 (20 mg), e
with phF1.6 and Tax (ﬁlled with pEF to 50 mg) were treated for 48 h with 10 mM of the
phF1.6 (20 mg) served as control. Luciferase assays (upper panel) and an immunoblot of Fa
with phF1.6 and pEFTax1 or the control vector pEF. Tax-transfected cells were treated wit
to luciferase assays (upper panel) and immunoblotting (lower panel). (e) After transfecti
ml, in water) or TPA (20 nM, in DMSO) or were left untreated (UT). Mean values were nor
and β-Actin (ActB) of Jurkat cells 48 h after treatment with 20 ng/ml TNF, 20 nM TPA or
were treated with TNF (20 ng/ml) or TPA (20 nM). The percentage of CD14þ cells was d
with PE-Cy5. Mean values of three independent experiments7SE are shown.Regulation of Fascin transcription varies between tissue, cell,
and cancer type and is achieved via promoter activation, silencing
elements, or via micro RNAs binding to the 3′ untranslated region
(3′UTR) (Hashimoto et al., 2011; Ma and Machesky, 2014). Diverse
cytokines, receptors, signaling pathways, and transcription factors
have been implicated in transcriptional activation of Fascin in
carcinomas, e.g. tumor necrosis factor (TNF), interleukin-6 (Snyder
et al., 2014), human epidermal growth factor receptor 2 (Grothey
et al., 2000), CREB (Hashimoto et al., 2009), or hypoxia-induciblethe human Fascin promoter. (a) Schematic representation of the luciferase construct
ing sites for the transcription factors NFAT (green), CREB (blue), and NF-κB (red).
promoter region (TRR) is indicated. (b–e) Jurkat T-cells were transfected with the
and results are shown as mean fold induction of RLU/protein normalized to the
performed in triplicate and results were evaluated using a t-test (*, Po0.05; **,
t), M47 (CREB-deﬁcient), M7 (NF-κB- and CREB-deﬁcient), or a control (pcDNA) and
t), 4-1BB wt prom (upper panel, white bars, representative result), or with phF1.6
ither together with pIκBα-DN (10 mg) or pcDNA (10 mg, control), or cells transfected
IKK-β inhibitor ACHP or DMSO (solvent). Transfection of pEF (30 mg) together with
scin, Tax-1 and ß-Actin (ActB) (lower panel) are shown. (d) Cells were cotransfected
h 1 mg/ml Cyclosporin A (CsA), DMSO (solvent), or left untreated (UT), and subjected
on of reporter constructs pGL3-Basic or phF1.6, cells were treated with TNF (20 ng/
malized to pGL3-Basic UT. The y-axis was cut at 140. (f) Immunoblot of Fascin, Tax-1
transfection with 50 mg pEFTax1 or 50 mg pEF. (g) SVT35 CD14-reporter Jurkat cells
etected 48 h after transfection by ﬂow cytometry using α-CD14 antibodies labeled
C.F. Mohr et al. / Virology 485 (2015) 481–491 483factor-1 (Zhao et al., 2014). Nevertheless, Fascin regulation in
leukemia is largely unknown. We could previously show that
Fascin is strongly upregulated in ATL-derived cells and in CD4þ
T-cells transformed by HTLV-1 or by the viral oncoprotein Tax.
Fascin contributes to the invasive potential of ATL-derived cells
(Kress et al., 2011). We were the ﬁrst to demonstrate that tran-
scriptional regulation of Fascin in ATL depends on NF-κB signaling(Kress et al., 2011), which was conﬁrmed in breast cancer (Snyder
et al., 2011). Beyond, we could show that NF-κB-dependent
induction of Fascin and its contribution to invasive migration are
also features of latent membrane protein 1 (LMP1), an oncoprotein
encoded by Epstein–Barr virus (Mohr et al., 2014), suggesting that
deregulation of Fascin by viral oncoproteins is a common
mechanism of viral oncogenesis.
C.F. Mohr et al. / Virology 485 (2015) 481–491484Details about the mechanism of Fascin induction by viral
oncoproteins are still lacking. Here, we report that the viral Tax
oncoprotein activates a 1.6 kb fragment of the human Fascin pro-
moter. Our study shows for the ﬁrst time that Tax-mediated
transcriptional induction of Fascin requires both NF-κB-dependent
promoter activation and a promoter-independent signaling path-
way that is inhibited by the Src family kinase (SFK) inhibitor PP2.
Hence, this is the ﬁrst study to implicate PP2, an inhibitor of
metastasis, in repression of Fascin.Results
A 1.6 kb fragment of the human Fascin promoter is regulated by Tax
Tax is a potent inducer of Fascin (Kress et al., 2011), however,
the detailed mechanism of Fascin induction by Tax is unknown.
Depending on cell and cancer type, several different regulatory
elements contribute to Fascin promoter activity (Hashimoto et al.,
2011; Ma and Machesky, 2014). To evaluate whether the Fascin
promoter is activated by the viral oncoprotein Tax and in T-lym-
phocytes, Jurkat T-cells were transfected with reporter constructs
(phF) harboring a luciferase gene under the control of serial 5′
deletions of the human Fascin promoter (Bros et al., 2003), ranging
from 3.1 kb (phF3.1) to 0.12 kb in length (phF0.12) (Fig. 1a). All
constructs contained the transcription start site (þ1) and the ﬁrst
123 bp upstream of the start site (þ123). Upon cotransfection of
an expression vector for Tax (pEFTax1) or a control vector (pEF),
luciferase assays revealed only background activity upon analysis
of the shortest promoter constructs phF0.12 and phF0.15, con-
ﬁrming earlier observations in dendritic cells (Bros et al., 2003)
(Fig. 1b). However, all constructs ranging from phF0.21 to phF3.1
exhibited basal activity signiﬁcantly exceeding the background
activity. phF0.21 carried the smallest promoter fragment to show
considerable reporter activity independent of the presence of Tax
(Po0.05), thus, comprising a functional core promoter. Among all
constructs tested, only the activity of construct phF1.6 was sig-
niﬁcantly transactivated by Tax (Po0.05). Therefore, the region
ranging from 1499 to 1325 was named Tax-responsive region
(TRR). Fascin promoter constructs longer or shorter than phF1.6
were not inducible by Tax despite sufﬁcient amount of Tax protein
to induce expression of endogenous Fascin (Fig. 1c). Taken toge-
ther, these data indicate that the Fascin promoter contains a core
promoter active in T-lymphocytes and a TRR containing positive
regulatory elements presumably surrounded by inhibitory
elements.
Tax-mediated activation of the Fascin promoter depends on NF-κB
To ascertain the signaling pathways that are important for Tax-
mediated induction of the 1.6 kb fragment of the Fascin promoter
(phF1.6), this region was analyzed for putative binding sites of
transcription factors that have been described in Tax-mediated
gene regulation including CREB, NF-κB, and nuclear factor of
activated T-cells (NFAT) (Grassmann et al., 2005; Qu and Xiao,
2011; Saggioro, 2011; Silbermann et al., 2008) (Fig. 2a). Bioinfor-
matics revealed several putative binding sites for CREB, one in the
TRR (1367/1344), two within the core promoter (47/22;
þ50/þ73), and four other CREB binding sites at (204/184;
-320/300; 354/333; 414/394). Moreover, the human
Fascin promoter harbors four binding sites for NF-κB transcription
factors between the TRR and the core promoter (1072/1048;
976/962; 430/411; 209/194). Finally, a putative NFAT
binding site is located within the TRR (1480/1460). To assess
the role of NF-κB and CREB signals in Tax-induced activation of
phF1.6, Tax mutants that functionally differentiate these twopathways were analyzed (Fig. 2b) (Smith and Greene, 1990). M22
is deﬁcient in NF-κB signaling, M47 in activation of the HTLV-1
promoter U3R via viral cAMP response element (v-CRE) sites, and
M7 in both pathways (Fig. 2b). First, we checked the functionality
of the Tax-mutants in luciferase assays in Jurkat T-cells. Consistent
with a previous publication (Smith and Greene, 1990), M22 had a
weaker effect on the HTLV-1 U3R than Tax1, while M47 and M7 did
not transactivate the U3R at all (Fig. 2b, upper panel, black bars).
Analysis of the NF-κB-dependent promoter of the costimulatory
receptor 4-1BB (Pichler et al., 2008) showed that the NF-κB-deﬁ-
cient mutants, M22 and M7, are indeed strongly impaired in
transactivation of 4-1BB wt prom compared to Tax and M47
(Fig. 2a, upper panel, white bars). Having conﬁrmed the func-
tionality of the Tax mutants, we measured their impact on acti-
vation of phF1.6 (Fig. 2b, lower panel). M22 and M7 did not induce
activation of phF1.6 compared with wild type (wt) Tax (pcTax1)
(Po0.01), conﬁrming earlier observations of Fascin expression
(Kress et al., 2011). In contrast, the CREB-deﬁcient mutant M47
could still induce activation of phF1.6 comparable to wt Tax,
although it was impaired in transcriptional induction of Fascin
(Kress et al., 2011), suggesting that promoter transactivation alone
is not sufﬁcient to induce Fascin. In conclusion, NF-κB, but not
CREB signals contribute to Tax-mediated transactivation of phF1.6.
To substantiate these ﬁndings, Jurkat T-cells were transfected with
phF1.6 together with Tax (pEFTax1) and, additionally, either a
chemical inhibitor of IKK-β, ACHP (10 mM, 48 h), was applied, or
cells were cotransfected with pIκBα-DN encoding a dominant
negative inhibitor of the classical NF-κB pathway (Fig. 2c). IκBα-
DN carries two point mutations at serines 32/36 to alanine,
thereby competing with endogenous IκBα for phosphorylation
and degradation (Voll et al., 2000). Both ACHP (Po0.05) and
pIκBα-DN (Po0.01) signiﬁcantly decreased Tax-induced phF1.6
activity (Fig. 2c, upper panel), and both experimental conditions
reduced the amount of Tax-induced endogenous Fascin protein
(Fig. 2c, lower panel). To control if Tax is dependent on NFAT to
activate phF1.6, Jurkat T-cells were cotransfected with phF1.6 and
pEFTax1 in the presence of 1 mg/ml of the NFAT inhibitor cyclos-
porin A (CsA). CsA did neither affect Tax-mediated activation of
phF1.6 (Fig. 2d, upper panel), nor did it affect Tax-induced
expression of endogenous Fascin protein. In conclusion, use of Tax-
mutants and speciﬁc inhibitors revealed that Tax depends on NF-
κB signals to activate the 1.6 kb fragment of the Fascin promoter.
To decipher if NF-κB-inducing compounds alone activate
phF1.6, Jurkat T-cells were transfected with phF1.6 and, addition-
ally, the NF-κB inducer TNF (20 ng/ml) or 12-O-tetra-
decanoylphorbol-13-acetate (TPA; 20 nM) was applied (Fig. 2e)
and compared with a control (pGL3-Basic). Contrary to cells
cotransfected with Tax (pEFTax1), both TNF and TPA did not acti-
vate the 1.6 kb fragment of the Fascin promoter. In accordance
with the latter ﬁnding, TNF and TPA did not induce endogenous
Fascin protein expression in Jurkat T-cells (Fig. 2f) compared with
cells transfected with Tax (pEFTax1). To show that NF-κB signaling
is active in presence of the concentrations of TNF and TPA used,
SVT35 Jurkat T-cells harboring an NF-κB-driven CD14 reporter
were analyzed (Fig. 2g) (Ting et al., 1996). Treatment with TNF or
TPA induced CD14 expression in around 80% of the cells, thereby
proving CD14 reporter activation and underlining the NF-κB-
inducing activity of either compound. Taken together these ﬁnd-
ings clearly show that NF-κB signals are important for Tax-medi-
ated activation of the 1.6 kb fragment of the Fascin promoter, but
NF-κB signals alone are neither sufﬁcient to induce the Fascin
promoter nor to induce Fascin protein expression.
Fig. 3. The isolated Tax-responsive promoter region (TRR) is inducible by Tax. (a) Scheme of the luciferase reporter constructs phF0.21 and phF-TRR, the latter carrying the
Tax-responsive promoter region (TRR) of the human Fascin promoter cloned upstream of the Fascin core promoter phF0.21. Putative transcription factor binding sites for
NFAT (green) and CREB (blue) are shown. The arrows indicate the location of a putative Tax-response element (TRE) and numbers indicate distances from the transcription
start point of the full-length human Fascin promoter. (b) Jurkat T-cells were cotransfected with luciferase reporter constructs phF0.21 or phF-TRR in combination with
pEFTax1 or pEF. After 48 h, luciferase activity was measured (upper panel). Results of three independent experiments performed in triplicates are shown as mean fold
induction of RLU/protein7SE and were compared to values of cells cotransfected with the mock vector pEF using a t-test (**, Po0.01). Immunoblots of Fascin, Tax-1 and β-
Actin were performed (lower panel).
Fig. 4. PP2 inhibits Tax-mediated induction of Fascin, but not Tax-mediated promoter transactivation. (a–c) Jurkat T-cells were transfected with pEFTax1 (40 mg), replenished
with 10 mg pEF, and coincubated with inhibitors ACHP, PP2, U0126, LY294002, Glivecs, DMSO (solvent control) or PP3 (negative control for PP2) for 48 h. Untreated cells (UT)
or cells transfected with 50 mg pEF served as controls. (a) Viability was measured by ﬂow cytometry using SYTOX AAdvanced and the percentage of SYTOX-negative cells
(viable cells) is depicted. (b) Quantitative PCR (qPCR) of Fascin mRNA. Copy numbers were normalized to those of β-Actin (ActB) and thereafter normalized to relative Fascin
expression of UT. Mean values of fold induction7SE are shown and were compared using a t-test (n¼3; **, Po0.01). (c) Immunoblot of Fascin, Tax-1 and ActB of cells
treated with PP2 in comparison to controls. Values indicate Fascin protein expression as detected by densitometry and normalized on PP3-treated cells (set as 1). (d,e) Jurkat
T-cells were cotransfected with luciferase reporter plasmids (d) phF1.6 or (e) pNF-κB-Luc and pEFTax1 or a control plasmid (pEF). Cells were treated with 5 mM of PP3, PP2,
the IKK-β inhibitor ACHP (positive control), or with DMSO (solvent control) for 48 h. Results are shown as mean RLU/protein7SE of three independent experiments
performed in triplicate and were compared using a t-test (*, Po0.05).
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Fig. 5. Tax-mediated Fascin induction is independent of the Src family kinase Lck. (a,b) Lck-deﬁcient JCaM1.6 cells were either transfected with pEFTax1 (30 mg), expression
plasmids pEF–Lck–myc (murine Lck; 20 mg), or pFJ-5′Lck (human Lck, 20 mg), or a combination of Tax and the Lck-expression plasmids. pEF served as negative control and
was used to adjust transfections to a total amount of 50 mg of DNA. Cells were harvested 48 h after transfection. (a) qPCR of FascinmRNA. Copy numbers were normalized to
those of β-Actin (ActB) and thereafter normalized to relative Fascin expression of untreated cells. Mean values of fold induction7SE are shown (n¼3). (b) Immunoblot of Lck,
Fascin, Tax-1 and ActB.
C.F. Mohr et al. / Virology 485 (2015) 481–491486An isolated Tax-responsive promoter region is inducible by Tax
So far, phF1.6, which carries a TRR, is the only Fascin promoter
construct identiﬁed to be inducible by Tax. Moreover, we observed
that neither NF-κB-inducing compounds nor the LMP1 oncopro-
tein transactivate phF1.6 (data not shown), although the latter is a
potent inducer of NF-κB and of Fascin (Mohr et al., 2014). Since the
promoter constructs longer or shorter than phF1.6 are not Tax-
responsive, the question was raised, if the TRR alone confers
responsiveness to Tax similar to an enhancer element. For this
purpose, the TRR was analyzed in more detail and cloned into a
vector with the 0.21 bp core promoter of Fascin (Fig. 3a), thereby
generating phF-TRR, which still contains a putative CREB and NFAT
site within the TRR, but lacks obvious NF-κB-responsive elements.
Additionally, the core promoter contains two further putative
CREB sites (47/22; þ50/þ73). The putative CREB binding site
within the TRR (1367/1344) harbors at (1360/1353) in
antisense orientation high similarity to a v-CRE, a Tax-response
element (TRE; TGACGTTG). Additionally, we identiﬁed a palin-
dromic TRE (TGACGTCA) (Giam and Xu, 1989) at (38/31)
within the CRE site of the core promoter. The latter is also heavily
ﬂanked by GC-rich regions, which is a characteristic of TREs in the
HTLV-1-promoter (Lenzmeier et al., 1998; Lundblad et al., 1998). To
control if the TRR is still inducible by Tax, phF-TRR was cotrans-
fected with pEFTax1 in Jurkat T-cells and compared to phF0.21
carrying the core promoter. The isolated Tax-responsive promoter
region was still responsive to Tax leading to 1.5 fold induction
compared with mock (Po0.01) (Fig. 3b). Reduction of the Tax
effect relative to phF1.6 (Fig. 1b) may be attributed to the lack of
putative NF-κB sites in phF-TRR. Since phF0.21 was not inducible
by Tax, the TRE located in the TRR may contribute to Tax-induced
activation of the human Fascin promoter. Thus, our data suggest
that both Tax functions, (1) activation of NF-κB (Fig. 2b and c) and
(2) activation of the TRR (Fig. 3) are required for induction of
Fascin.
Induction of Fascin by Tax is not only dependent on NF-κB, but also
inhibited by the Src family kinase (SFK) inhibitor PP2 in
T-lymphocytes
Since putative NF-κB-binding sites are absent from the TRR
(Figs. 2A and 3A), and pharmaceutical activation of NF-κB was not
sufﬁcient to activate the Tax-responsive Fascin promoter phF1.6
(Fig. 2e), a screening was conducted to identify additional signal-
ing pathways that contribute to Tax-mediated activation of Fascin.
Therefore, Tax-transfected Jurkat T-cells were cultured in thepresence of different signaling pathway inhibitors. The NF-κB
inhibitor ACHP served as positive control for Fascin inhibition
(Kress et al., 2011). PP2 is primarily an inhibitor of SFK signaling
(Bain et al., 2007), while PP3 is an inactive form of PP2 and served
as negative control. Additionally, inhibitors of the mitogen acti-
vated protein kinase (MAPK) pathway (U0126), the phosphatidy-
linositol-3-kinase (PI3K) pathway (LY294002), and of Abl tyrosine
kinases and of T-cell receptor-mediated T-cell activation (Glivec)
(Lin et al., 2013; Seggewiss et al., 2005) were analyzed. None of the
tested inhibitors affected cell viability compared with the solvent
control DMSO (Fig. 4a). Among all applied inhibitors, only ACHP
and PP2 signiﬁcantly affected Fascin mRNA induction by Tax. ACHP
led to a reduction from 13-fold to 1-fold (Fig. 4b, Po0.01), con-
ﬁrming earlier observations (Kress et al., 2011). In the presence of
PP2, Fascin transcript levels decreased from 14-fold to 8-fold
(Fig. 4b, Po0.01). The impact of PP2 on Tax-mediated Fascin
induction was conﬁrmed on protein level (Fig. 4c), but was not
dose-dependent (data not shown). This reveals that Fascin
induction by Tax is not only regulated by NF-κB, but also impaired
by the SFK inhibitor PP2 in transiently transfected T-lymphocytes.
PP2 does not inhibit Tax-mediated activation of the 1.6 kb fragment of
the Fascin promoter
As Tax-mediated activation of the 1.6 kb fragment of the Fascin
promoter is regulated by NF-κB, it remained to be determined, if
the newly-discovered Fascin inhibitor PP2 is also involved in
promoter transactivation. Addition of PP2 (5 mM) to Jurkat T-cells
transfected with Tax and phF1.6 did not affect Tax-mediated
induction of phF1.6 (Fig. 4d), while the IKK-β inhibitor ACHP
(10 mM) diminished Tax-mediated transactivation of phF1.6
(Po0.05). To exclude an indirect effect of PP2 on NF-κB signaling,
luciferase assays with an NF-κB-dependent luciferase reporter
plasmid were performed (Fig. 4e). NF-κB-dependent luciferase
activity was induced by Tax and blocked by the NF-κB inhibitor
ACHP, while PP2 was not able to reduce Tax-mediated NF-κB
reporter activity. These results indicate that PP2 has no effect on
Tax-induced NF-κB activity. Furthermore, Tax-mediated Fascin
promoter activation is dependent on NF-κB, but independent of
signaling pathways inhibited by PP2.
Tax-mediated Fascin induction is independent of the Src family kinase
Lck
PP2 blocks a speciﬁc spectrum of SFKs, and the strongest sup-
pression is observed for lymphocyte-speciﬁc protein tyrosine
Fig. 6. PP2 inhibits Fascin expression in HTLV-1-/Tax-transformed T lymphocytes. (a,b) HTLV-1-transformed MT-2 cells (left panel) and Tax-transformed Tesi cells (right
panel) were treated with the IKK-β inhibitor ACHP (2.5 mM, positive control) and increasing amounts of PP2 (5, 10, 25, 50 mM) for 48 h. PP3 (50 mM, negative control for PP2)
and DMSO (solvent) served as controls. (a) Viability was measured by ﬂow cytometry using LIVE/DEADs ﬁxable far red stain and the percentage of LIVE/DEADs -negative cells
is depicted. Etoposide (15 mM) served as positive control for cell death. (b) qPCR of Fascin mRNA. Copy numbers were normalized to those of β-Actin (ActB). Relative copy
numbers of Fascin in DMSO-treated cells were set to 100%. Mean values of % Fascin mRNA7SE were compared using a t-test (nZ4; *, Po0.05).
Fig. 7. Model of Tax-mediated regulation of Fascin. Tax-mediated transcriptional
induction of Fascin requires NF-κB- and TRE-dependent promoter activation, and a
novel, promoter-independent, but PP2-inhibitable signaling pathway.
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in T-cell receptor signaling. Since Lck is downregulated by Tax and
in HTLV-1-infected cells (Koga et al., 1989; Lemasson et al., 1997),
we used Lck-deﬁcient Jurkat T-cells (JCaM1.6) (Straus and Weiss,
1992) to test if Tax-mediated activation of Fascin expression occurs
independent of Lck. We found that even in the absence of Lck, Tax
was able to induce Fascin mRNA (Fig. 5a) and protein (Fig. 5b).
Reconstitution of Lck by cotransfection of expression plasmids
encoding mouse Lck (pEF-Lck) or human Lck (pFJ-5′Lck) did not
alter the extent of Tax-induced Fascin expression in JCaM1.6 cells
(Fig. 5a and b). Thus, the SFK Lck is not involved in Tax-mediated
Fascin induction.Regulation of Fascin in HTLV-1/Tax-transformed T-lymphocytes is
inhibited by PP2
To test the impact of PP2 on Fascin expression in a more rele-
vant context of HTLV-1 pathogenesis, HTLV-1 transformed T-lym-
phocytes, MT-2 (Fig. 6, left panels), and Tax-transformed T-lym-
phocytes, Tesi (Fig. 6, right panels), were treated with increasing
concentrations of PP2 for 48 h. Cell viability was not signiﬁcantly
affected by treatment with PP2, PP3, or the IKK-β inhibitor ACHP
compared with DMSO, but was decreased by the topoisomerase
inhibitor etoposide (Po0.05; Fig. 6a). ACHP, a known inhibitor of
Fascin in these two cell systems (Kress et al., 2011), was used as
control. In both transformed T-cell lines, Fascin mRNA levels sig-
niﬁcantly decreased in the presence of 25 and 50 mM PP2 (Fig. 6b),
while lower concentrations of PP2 had no signiﬁcant effect. In MT-
2 cells, Fascin diminished to 74% and 57% in presence of PP2
(25 mM and 50 mM, respectively; Po0.05), and to 72% (Po0.05) in
presence of ACHP (2.5 mM). In Tesi cells, the same conditions
reduced Fascin to 50% and 40% (Po0.05) for PP2, and to 47% for
ACHP. While PP2 reduced Fascin upon transient expression of Tax
in Jurkat T-cells already at low concentrations (5 mM; Fig. 4b and
c), higher concentrations of PP2 (25 mM and 50 mM) were required
in continuously Tax-expressing cell lines MT-2 and Tesi (Fig. 6b).
This discrepancy may be attributed to differences in signaling
intensities and pathways between cells expressing Tax transiently
compared to Tax-transformed cells expressing Tax continuously.
Taken together, Fascin regulation in HTLV-1-/Tax-transformed
T-lymphocytes is not only dependent on NF-κB, but also relies on a
novel PP2-sensitive signaling pathway. Thus, Tax-induced Fascin
expression is regulated by NF-κB-dependent and TRR-dependent
promoter activation, and by a novel promoter-independent, but
PP2-inhibitable signaling pathway (Fig. 7).
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Upregulation of the actin-bundling protein Fascin is a common
feature of several types of cancer and is associated with poor
prognosis, enhanced migration, and invasion (Hashimoto et al.,
2011; Jayo and Parsons, 2010; Tan et al., 2013). However, regula-
tion of Fascin transcription strongly varies between cell, tissue, and
cancer types (Hashimoto et al., 2011; Ma and Machesky, 2014). In
this study, we provide a molecular mechanism for the regulation
of Fascin by the viral oncoprotein Tax. The signiﬁcance of our
ﬁndings lies in the identiﬁcation of a triple mode of transcriptional
induction of Fascin by Tax, which requires (1) NF-κB-dependent
promoter activation, (2) a Tax-responsive region (TRR) in the
Fascin promoter, and (3) a promoter-independent mechanism. The
latter identiﬁes Fascin as a novel target of PP2, an inhibitor of
metastatic spread (Nam et al., 2002).
We identiﬁed a 1.6 kb fragment of the human Fascin promoter
(phF1.6) upstream of the transcription start site that is inducible
by Tax. The Tax-speciﬁc effect on the Fascin promoter was lost in
promoter constructs shorter or longer than phF1.6, suggesting that
this Tax-responsive promoter region (TRR; 1499/1325) is sur-
rounded by repressor elements, a fact that could also be demon-
strated in mature DCs (Bros et al., 2003), proposing that there are
mechanisms in Fascin regulation conserved between DCs and Tax-
expressing T-cells. Tax-mediated activation of phF1.6 could be
attributed to NF-κB signaling by use of NF-κB-deﬁcient Tax
mutants and by inhibitors of NF-κB. This is in line with the
necessity of NF-κB signaling for transcriptional induction of Fascin
by Tax (Kress et al., 2011), although it cannot be excluded that NF-
κB signaling contributes to strategies of Fascin regulation other
than promoter transactivation. LMP1 also induces Fascin expres-
sion depending on NF-κB (Mohr et al., 2014), but, contrary to Tax,
LMP1 does not transactivate phF1.6 (data not shown). Beyond, TNF
and TPA, potent inducers of NF-κB (Chang et al., 1994; Hoesel and
Schmid, 2013), did not affect Fascin expression or transactivation
of phF1.6 in Jurkat T-cells contrary to results obtained in other cell
types (Onodera et al., 2009; Snyder et al., 2014). Thus, despite
induction of the same signaling pathway, the ﬁne-tuning of tran-
scriptional activation varies between different oncoproteins and
cell systems.
The identiﬁcation of a TRR with putative enhancer abilities and
similarities to Tax-responsive elements (TRE) might explain the
responsiveness of the human Fascin promoter to Tax independent of
the presence of NF-κB-responsive elements. The TRE is a 21 bp triple
repeat in the HTLV-1-promoter containing an octamer motif TGACG
(T/A)(C/G)(T/A) homologous to cellular CRE sites (Giam and Xu,
1989; Jeang et al., 1988). Tax activates viral transcription through
association with phosphorylated CREB and the adjacent minor
groove GC-rich DNA, which is usually lacking in cellular CREs (Kim
et al., 2010). Thus far, only few CRE-dependent target genes of Tax
have been identiﬁed, e.g. cyclin D1 (Kim et al., 2010) and GEM, which
encodes a small GTP-binding protein (Chevalier et al., 2014). We
previously found that the CREB-deﬁcient Tax mutant M47 is
impaired in transcriptional induction of Fascin (Kress et al., 2011).
Since CREB acts as a positive regulator of Fascin in several other
metastatic human cancer cells (Hashimoto et al., 2009; Li et al.,
2013), we cannot exclude a contribution of the CREB signaling
pathway to Tax-mediated induction of Fascin. In contrast, we dis-
covered that M47 can still induce activation of phF1.6 comparable to
wildtype Tax, suggesting that promoter transactivation alone is not
sufﬁcient to fully activate Fascin transcription. This is supported by
our ﬁnding that a novel, promoter- and NF-κB-independent strategy
contributes to Tax-mediated Fascin regulation.
PP2, a strong inhibitor of Src family kinases (SFK) (Geahlen
et al., 2004), signiﬁcantly impaired Tax-induced Fascin expression
in T-cells without affecting NF-κB signaling or the Fascin promoterphF1.6. SFK activity is deregulated in many types of cancer, affects
numerous cellular substrates, and contributes to viral transfor-
mation (Katsch et al., 2012; Parsons and Parsons, 2004; Reynolds
et al., 2014). Besides, Src, the prototype SFK, is important for cancer
invasion (Guarino, 2010). In human T-cells, PP2 inhibits the SFKs
Lck and FynT, and, as a consequence, tyrosine kinase-dependent
T-cell proliferation (Geahlen et al., 2004). Upon HTLV-1 transfor-
mation, SFK expression patterns switch from Lck and FynT to Lyn
and FynB (Shuh et al., 2011; Weil et al., 1999). Downstream
pathways of SFK that can be inhibited by PP2 include the janus
kinase (Jak)/signal transducer and activator of transcription (STAT)
pathway (Shuh et al., 2011). The Jak/STAT pathway is upregulated
in different types of cancer including ATL and represents a
potential therapeutic target (Ju et al., 2011). In breast and gastric
cancer, an NF-κB- and STAT-dependent mechanism of Fascin
induction has already been described. Although TNF and inter-
leukin-6 induce binding of a complex of NF-κB p50:p65 and STAT3
to the Fascin promoter at position (1095/979) (Snyder et al.,
2014, 2011; Yao et al., 2014), it is unlikely that this mechanism is
responsible for Tax-mediated induction of Fascin: (1) both STAT3
and STAT5 are constitutively activated in HTLV-1-transformed cells
(Migone et al., 1995), but Tax only induces STAT5 and not STAT3
(Nakamura et al., 1999), and the latter is inactive in Tax-trans-
formed lymphocytes (Fung et al., 2005; Grassmann et al., 1989).
(2) Complexes of the SFK Lyn with Jak3 and Jak3:STAT5 have been
identiﬁed in HTLV-1-transformed cells and their activity is inhib-
ited by PP2, but Jak3:STAT3 complexes are lacking (Migone et al.,
1995; Shuh et al., 2011). (3) The promoter construct phF1.2, which
harbors the STAT/NF-κB-binding site at (1095/979) is not
responsive to Tax. (4) Finally, PP2 does not impair Tax-mediated
activation of phF1.6.
Apart from blocking SFKs, PP2 diminishes signaling of p38α/
p38ß MAPK, casein kinase 1δ (CK1 δ), receptor-interacting protein
2 (RIP2), cytoplasmic tyrosine kinase (CSK), and cyclin G-asso-
ciated kinase (GAK) (Bain et al., 2007). Amongst those, p38 MAPK
has been implicated in transcriptional elongation (Kumari et al.,
2013). Tax is a potent inducer of certain transcription elongation
factors (Mann et al., 2014), and our probe used in qPCR spans an
exon junction between exon 4/5 in the 3′ part of the Fascin tran-
script. Therefore, the inhibitory role of PP2 on Fascin transcripts
could be explained by deregulating transcriptional elongation of
Fascin rather than promoter transactivation, which is unaffected by
PP2. Interestingly, PP2 impaired migration and invasion of human
gastric cancer cells, accompanied by an inhibition of p38 phos-
phorylation (Ma et al., 2014).
Regulation of gene expression is frequently inﬂuenced by cis-
acting enhancer/suppressor elements located within introns, in
the 3′UTR, or even in exons of a gene. Potential silencing elements
located distal from the transcription start site (Bros et al., 2003;
Hashimoto et al., 2009) and in the ﬁrst exon of Fascin (Hou et al.,
2009) have been proposed to be involved in Fascin gene regula-
tion. Therefore, it is possible that PP2, or even NF-κB inhibitors,
block Tax-induced pathways that impair these silencers. Beyond,
several micro RNAs (miRs) bind to the 3′UTR of Fascin. miR-133b,
miR-133a, miR-143, and miR145 are associated with negative
regulation of Fascin in different types of cancer, e.g. miR-145 in
breast (Gotte et al., 2010), bladder (Chiyomaru et al., 2010), and
colon cancer (Feng et al., 2014). Deregulation of miRs has also been
associated with HTLV-1-pathogenesis (Pichler et al., 2008), and
interestingly, miR-145 is downregulated in PBMCs from aggres-
sive-type ATL patients and associated with a worsened prognosis
(Xia et al., 2014; Yeung et al., 2008). Thus, it is also conceivable that
Tax affects the Fascin 3′UTR.
Our data shows that PP2 represses Fascin shed new light on the
ability of PP2 to impair the invasive capacity of a variety of can-
cers: (1) in ATL, the docking protein Cas-L results in markedly
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heavily tyrosine phosphorylated by focal adhesion kinase and SFKs
(Iwata et al., 2005), and thus, inhibited by PP2 (Tsai et al., 2014).
(2) PP2 restores the E-cadherin/catenin cell adhesion system in
human epithelial cancer cells and it reduces cancer metastasis in
mice (Nam et al., 2002). This is in line with ﬁndings showing that
knockdown of Fascin signiﬁcantly represses invasiveness of
hepatocellular carcinoma cells and induces E-cadherin expression
(Hayashi et al., 2011). (3) In pancreatic ductal adenocarcinoma
cells, PP2 is a powerful inhibitor of transforming growth factor-β-
induced cell invasion and inhibits induction of the invasion-asso-
ciated matrix metalloproteinase-2 (MMP-2) and MMP-9 genes
(Bartscht et al., 2012). Interestingly, Fascin overexpression pro-
motes invasion by elevating MMP-2 expression (Zhao et al., 2014),
providing the possibility that PP2 affects MMP-2 via Fascin. Thus,
targeting Fascin by PP2 might be relevant to several types of
metastatic cancer.
Taken together, we show for the ﬁrst time that Tax-mediated
transcriptional induction of Fascin requires NF-κB- and TRR-
dependent promoter activation, and a promoter-independent, but
PP2-sensitive signaling pathway. Our study is the ﬁrst to implicate
PP2, an inhibitor of metastatic spread (Bartscht et al., 2012; Nam
et al., 2002), in repression of Fascin in cancer.Materials and methods
Cell culture
The T-cell lines MT-2 (HTLV-1 in vitro transformed) (Yoshida
et al., 1982), Tesi (Tax-transformed) (Schmitt et al., 1998), Jurkat
(from acute lymphoblastic leukemia) (Schneider et al., 1977), and the
Jurkat-derived cell lines SVT35 (carrying an NF-κB-driven CD14
reporter gene) (Ting et al., 1996), and JCaM1.6 (deﬁcient for the
lymphocyte-speciﬁc protein tyrosine kinase (lck) gene (exon 7)) (Straus
and Weiss, 1992) were cultured in RPMI 1640 with glutamine
(GIBCO, Life Technologies, Darmstadt, Germany), penicillin/strepto-
mycin, and 20% fetal calf serum (FCS; Tesi) or 10% FCS (all other cell
lines). Media for Tesi and Jurkat cell lines contained 45% Panserin
401 (PAN-Biotech, Aidenbach, Germany) in addition, and media for
Tesi cells were supplemented with 40 U/ml interleukin-2 (Roche
Diagnostics GmbH, Mannheim, Germany). Cell lines were checked
for integrity by DNA proﬁling of eight different and highly poly-
morphic short tandem repeat loci (DSMZ, Braunschweig, Germany).
Plasmids and cloning
Luciferase reporter constructs of the human Fascin promoter
(phF3.1) and truncations thereof (phF2.7–phF0.21) have been
described (Bros et al., 2003). The luciferase reporter construct phF-
TRR was cloned using primers 5′-ATTTGGTACCGCACCATCA-
CACCCAGCTAA-3′ with a KpnI restriction site (in bold) and 5′-
ATTTGGGCCCGCCCCTGGCAACCCC-3′ with an ApaI restriction site
(in bold) for ampliﬁcation of the region (1499 to 1325) of
phF3.1. Fragments were cloned into phF0.21 via KpnI/ApaI sites.
Luciferase reporter vectors of the HTLV-1 promoter (HTLV-1 U3R)
and of the human 4-1BB promoter (4-1BB wt prom) have been
described (Mann et al., 2014; Pichler et al., 2008). Expression
plasmids for wildtype (wt) Tax pEFTax1 (in pEFneo) and the con-
trol plasmid pEFneo were kindly provided by Dr. Higuchi and
Dr. Fujii (Shoji et al., 2009). Expression plasmids pEF–Lck–myc for
mouse Lck (Witte et al., 2008) and pFJ-5′Lck for human Lck
(Albrecht et al., 1999) with a 5′ deletion in the non-coding region
have been described. Additionally, plasmids for wt-Tax driven by a
CMV promoter (pcTax) (Rimsky et al., 1988), the NF-κB-deﬁcient
Tax mutant M22, the CREB-deﬁcient Tax mutant M47, and thedouble-deﬁcient Tax mutant M7 (Smith and Greene, 1990), a
dominant negative inhibitor of IkBα (pIkBα-DN) (Voll et al., 2000),
pcDNA3.1 (Life Technologies GmbH, Darmstadt, Germany), and the
luciferase-reporter vector without eukaryotic promoter and
enhancer sequences pGL3-Basic (Promega, Mannheim, Germany)
were used.
Inhibitors and NF-κB stimuli
The following inhibitors were dissolved in DMSO and used at the
indicated concentrations for 48 h: IKK-β inhibitor ACHP (2-Amino-
6-(2-(cyclopropylmethoxy)-6-hydroxyphenyl)-4-(4-piperidinyl)-3-
pyridinecarbonitrile) (Merck, Darmstadt, Germany), Src family
kinase inhibitor PP2 (4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyr-
azolo[3,4-d]pyrimidine) (Merck), a negative control for PP2, PP3 (4-
amino-7-phenylpyrazolo[3,4-d]pyramidine) (Merck), Bcr-Abl kinase
inhibitor Glivec (Gleevec, imatinib, STI571; Novartis, Nuremberg,
Germany), MAPK/ERK kinase inhibitor U0126 (1,4-diamino-2,3-
dicyano-1,4-bis[2-aminophenylthio] butadiene) (Cell Signaling
Technology (CST), Danvers, MA, USA); and phosphoinositide
3-kinase inhibitor LY294002 (CST). Jurkat and SVT35 cells were
stimulated for 48 h with TNF (20 ng/ml; Immunotools, Friesoythe,
Germany) dissolved in water or 20 nM TPA (12-O-tetra-
decanoylphorbol-13-acetate)/PMA (phorbol-12-myristate-13-acet-
ate) (CST) dissolved in DMSO.
Transient transfection by electroporation
Transient transfection was performed as described (Mohr et al.,
2014). Brieﬂy, 1107 Jurkat T-cells were transfected by electro-
poration using a total amount of 50 μg plasmid DNA. To block NF-
κB signaling, 10 μg of pIκBα-DN were used. Cells were harvested
48 h after transfection. The amount of green ﬂuorescent protein
(GFP) expressed from transfected pmaxGFP plasmid (Amaxa/
Lonza) was used to evaluate transfection efﬁciency by ﬂow cyto-
metry (not shown).
Luciferase assays
Jurkat T-cells (5106 cells) were transfected in triplicates by
electroporation using 20 mg of reporter plasmid and 30 mg of
expression plasmids and harvested 48 h after transfection. Luciferase
activity was measured as described (Mann et al., 2014) using an
Orion Microplate Luminometer (Berthold, Pforzheim, Germany). RLU
was normalized to protein concentration determined by Bradford
assay. Additionally, protein lysates were obtained as described
(Mohr et al., 2014). Lysates were sonicated after the freeze-and-thaw
lysis for 320 s and processed for immunoblotting.
Immunoblots
Protein lysates were obtained 48 h after transfection and wes-
tern blot was performed as described (Mohr et al., 2014). Immu-
noblots were probed using rabbit polyclonal antibodies anti-Lck (BD
Biosciences; Heidelberg, Germany), mouse monoclonal antibodies
anti-Fascin (55K-2; Dako Deutschland GmbH, Hamburg, Germany),
anti-β-actin (ACTB; AC-15; Sigma), and mouse antibodies to Tax-1,
(provided by B. Langton through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH) (Langton et al.,
1988). Secondary antibodies conjugated with horseradish perox-
idase were obtained from GE Healthcare (Little Chalfont, UK). At
least three independent experiments were performed and one
representative result is shown. Densitometry was performed using
Advanced Image Data Analyser (AIDA Version 4.22.034, Raytest
Isotopenmessgeräte GmbH, Straubenhardt, Germany).
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Cell surface markers were stained with monoclonal antibodies
anti-CD14-PE-Cy5 (1 h; Immunotools, Germany). Cell death was
detected using SYTOX AAdvanced (Paciﬁc Blue™ Annexin V/
SYTOXs AADvanced™ for ﬂow cytometry, Life Technologies) or, if
ﬁxation in 2% paraformaldehyde was necessary, LIVE/DEADs ﬁx-
able far red stain (Life Technologies).
Quantitative real-time RT-PCR (qPCR)
Total cellular RNA was isolated and qPCR of Fascin and ß-Actin
(ACTB) transcripts was performed as described (Mohr et al., 2014).
Brieﬂy, primers ACTB-fwd: 5′-CCTCGCCTTTGCCGA-3, and ACTB-
rev: 5′-TGGTGCCTGGGGCG-3, and the FAM (6-carboxy-
ﬂuorescein)/TAMRA (tetramethylrhodamine)-labeled probe 5′-
FAM-CCGCCGCCCGTCCACACCCGCC-3′-TAMRA were used. For
quantitation of Fascin, a TaqMan Gene Expression Assay (Hs0097-
9631_g1) was used. Expression levels were calculated by inter-
polation from standard curves generated from plasmids carrying
the respective target sequences and computing the mean of tri-
plicate samples. Each sample was measured in at least three bio-
logical replicates. ACTB was used for normalization.
Bioinformatics and statistics
For prediction of transcription factor binding sites at the
human Fascin promoter, MATInspector (Genomatix, Munich,
Germany) was used (Cartharius et al., 2005). For statistical analy-
sis, Microsoft Ofﬁce Excel was applied and t-tests (unpaired) were
performed to detect signiﬁcant differences.Acknowledgments
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